← Back to Search

Mother's Recorded Voice for Premature Infants

N/A
Waitlist Available
Led By Narendra Dereddy, MD
Research Sponsored by AdventHealth
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 23 days
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to help extremely preterm infants and their mothers by playing a recording of the mother's voice to the baby in the incubator. The goal is to reduce parental stress, anxiety, and depression while also stabilizing or improving the baby's vital signs. The mother's voice provides comfort to the baby and helps mothers feel more connected and less helpless.

Who is the study for?
This trial is for mothers over 18 with preterm infants born between 26 and nearly 31 weeks of gestation, without major congenital or chromosomal anomalies. The mothers must be willing to record their voice and complete questionnaires about their feelings and stress levels.
What is being tested?
The study tests the effect of playing a mother's recorded voice to her extremely preterm infant in the NICU when she can't be there. It aims to see if this can reduce maternal depression, anxiety, stress, and improve feelings towards the baby.
What are the potential side effects?
There are no direct medical side effects expected from this intervention as it involves only playing audio recordings. However, emotional responses may vary among participants.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 23 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 23 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Maternal response to Depression, Anxiety, and Stress Scale(DASS)
Secondary study objectives
Feelings questionnaire
Incidence of apneas, bradycardias and desaturation episodes

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Maternal voiceExperimental Treatment1 Intervention
Mother's voice will be played for 1 week between week 2 and 3 of life
Group II: ControlActive Control1 Intervention
NO intervention between week 2 and 3

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Postpartum Depression (PPD) include selective serotonin reuptake inhibitors (SSRIs) and non-pharmacological interventions like cognitive-behavioral therapy (CBT) and emotional support. SSRIs work by increasing serotonin levels in the brain, which helps improve mood and emotional stability. Non-pharmacological treatments, such as the Mother's Recorded Voice intervention, provide psychological support and enhance mother-infant bonding. These treatments are essential for PPD patients as they address both the biological and emotional aspects of the disorder, promoting overall mental health and strengthening the mother-infant relationship.

Find a Location

Who is running the clinical trial?

DraegerUNKNOWN
1 Previous Clinical Trials
22 Total Patients Enrolled
AdventHealthLead Sponsor
115 Previous Clinical Trials
31,298 Total Patients Enrolled
1 Trials studying Premature Birth
80 Patients Enrolled for Premature Birth
Narendra Dereddy, MDPrincipal InvestigatorAdventHealth
1 Previous Clinical Trials
80 Total Patients Enrolled
1 Trials studying Premature Birth
80 Patients Enrolled for Premature Birth

Media Library

Maternal voice Clinical Trial Eligibility Overview. Trial Name: NCT04559620 — N/A
Premature Birth Research Study Groups: Maternal voice, Control
Premature Birth Clinical Trial 2023: Maternal voice Highlights & Side Effects. Trial Name: NCT04559620 — N/A
Maternal voice 2023 Treatment Timeline for Medical Study. Trial Name: NCT04559620 — N/A
~15 spots leftby Nov 2025